IDBS partnered with Alchemi to connect AI agents to drug-development data inside the IDBS Polar platform, targeting faster and compliant preparation of regulatory filings. The collaboration is aimed at a persistent CMC bottleneck: teams often spend months assembling reports and reconstructing process histories, while many AI tools risk breaking auditability by pulling data out of validated systems. IDBS said linking Alchemi’s purpose-built agents to Polar’s governed data backbone can keep a traceable compliance trail while drafting documents such as CMC technical reports, clinical study reports, and submission dossiers faster, citing customer deployments where documents were produced up to 70% faster.